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T ET proteins maintain appropriate patterns of gene expression through epigenetic mechanisms that are relevant in stem cell and cancer biology 1 . Extensive studies on TET functions in mammalian gene regulation and chromatin dynamics have highlighted the contribution of a number of sequence-specific DNAbinding transcription factors such as NANOG, PRDM14, PU.1, and WT1 (reviewed by Wu and Zhang 2 ) to 5hmC deposition at the genome, which leads to active demethylation of target genes. Whereas 5mC modification of RNA is firmly established 3 , the potential roles of TET proteins in mediating 5mC-to-5hmC oxidation in RNA are just beginning to be appreciated [4] [5] [6] [7] [8] .
Pluripotent mouse embryonic stem cells (ESCs) are derived from the inner cell mass of the preimplantation blastocyst. ESCs characteristically suppress the transcription of most ERVs 9 but fluctuate with MERVL activity in the two-cell (2C)-like population with an expanded potency 10 . ESCs express all components of the methylation and demethylation pathways, with all oxidized forms of 5mC detected at the DNA level. Despite extensive research into the role of TET proteins in genome regulation, little is known about their functions in controlling ERVs, which make up 8-10% of mouse and human genomes.
Here we defined the TET2 interactome in mouse ESCs and identified the RNA-binding protein PSPC1 as a binding partner of TET2. We show that TET2 can be recruited to chromatin in an RNA-dependent manner through its physical association with PSPC1. By identifying RNA targets of PSPC1, we demonstrated that PSPC1, while binding to MERVL transcripts, recruits TET2 function for both transcriptional and post-transcriptional regulation of MERVL through HDAC1/2-mediated repression and RNA hydroxymethylation (5hmC)-mediated degradation.
Results
TET2 interaction with PSPC1 is required for recruitment to chromatin. To identify factors that may regulate TET2 chromatin binding, we investigated the TET2 interactome in mouse ESCs. Using a 3× Flag-tagged Tet2-knockin ESC line, we carried out affinity purification coupled with mass spectrometry analysis of TET2-containing protein complexes ( Supplementary Fig. 1a-c) , following our well-established strategies 11, 12 . Among the top TET2interacting partners, we found the nuclear protein PSPC1 ( Fig. 1a , Supplementary Fig. 2a and Supplementary Table 1 ). The interaction between PSPC1 and TET2 was further confirmed by immunoprecipitation and coimmunoprecipitation experiments (Fig. 1c) , and was not compromised by the absence of other TET2-interacting partners such as OGT, SIN3A and NONO ( Fig. 1a and Supplementary  Fig. 2b,c) . Pspc1 showed a gene expression pattern similar to that of Tet2 across multiple tissues, including much higher enrichment in pluripotent cells than in somatic mouse embryonic fibroblasts ( Fig. 1b and Supplementary Fig. 2d,e) .
To test the effect of PSPC1 loss on TET2 chromatin occupancy, we analyzed TET2 levels in pure chromatin extracts after PSPC1 knockdown, and observed reduced occupancy (< 30%) of TET2 ( Fig. 1d and Supplementary Fig. 3a) . Notably, knockdown of PSPC1 did not dramatically affect ESC properties ( Supplementary  Fig. 3b-d) , which is similar to what is observed after the loss of TET2 function 13, 14 . These results suggest that the partnership between TET2 and PSPC1 may be necessary for proper function of TET2 at the chromatin level, although other TET2 partners could also participate in its recruitment, given that an appreciable level of TET2 still remained at the chromatin after PSPC1 depletion ( Figs. 1d and 2b ).
PSPC1 recruits TET2 to chromatin through RNA. Because PSPC1 is an RNA-binding protein, we explored the possibility that its RNAbinding ability could be relevant to TET2 recruitment, similar to what has been observed for other transcription factors and epigenetic regulators 15, 16 . To distinguish RNA-dependent from RNAindependent functions of PSPC1 in TET2 recruitment, we used the CRISPR-Cas9 nuclease system to generate a Pspc1-knockout (KO) ESC line ( Supplementary Fig. 4a,b) , and then rescued PSPC1 loss with Piggybac vectors expressing either wild-type PSPC1 or PSPC1 bearing four mutations in its RNA-binding domains 17 (F118A, F120A, K197A and F199A; hereinafter referred to as PSPC1Mut) ( Fig. 2a and Supplementary Fig. 4c,d ). We found that whereas the physical interaction between PSPC1 and TET2 was independent of PSPC1 RNA-binding capacity ( Fig. 2a and Supplementary Fig. 4e ), both TET2 ( Fig. 2b and Supplementary Fig. 4f ) and PSPC1 ( Fig. 2c ) chromatin occupancies were largely dependent on intact RNAbinding domains of PSPC1.
We next explored whether PSPC1 can mediate TET2-RNA interactions. We adapted an RNA immunoprecipitation protocol 18 to develop an in vitro RNA immunoprecipitation approach, termed iv-RIP, wherein PSPC1 or TET2 protein complexes were affinitypurified in the absence of endogenous nucleic acids, and their abilities to interact with total RNA were subsequently assayed ( Fig. 2d ).
Our results indicate that TET2 protein complexes interact with RNA species in a PSPC1-dependent manner, both in vitro ( Fig. 2d and Supplementary Fig. 5a ) and in vivo ( Supplementary Fig. 5b ). In contrast, PSPC1 binding to RNA was independent of TET2 ( Supplementary Fig. 5c ). Anti-TET2
Anti-H3
Anti-PSPC1 Given that TET2 chromatin recruitment is facilitated by PSPC1 RNA-binding properties, we hypothesized that transcriptional inhibition might affect chromatin targeting of TET2. We treated ESCs with α -amanitin briefly to induce global transcription inhibition while avoiding TET2 protein changes ( Fig. 2e , left), and confirmed by nucleosome pulldown that TET2 binding to chromatin was reduced after transcriptional inhibition compared with that in untreated cells ( Fig. 2e, right) .
Characterization of the RNA interactome involved in PSPC1-TET2 chromatin occupancy. To characterize the RNA interactome of PSPC1 involved in the binding and maintenance of PSPC1 and TET2 at chromatin, we carried out cross-linking followed by Flag immunoprecipitation and high-throughput sequencing (CLIP-seq) to identify PSPC1-associated RNA species in ESCs overexpressing 3× Flag-and biotin-tagged PSPC1 ( Fig. 3a , left, and Supplementary Table 2 ). Supporting a functional connection between PSPC1 and TET2, an in silico analysis of the available TET2 ChIP-seq dataset for ESCs 19 showed high correlation between TET2 occupancy at DNA regions and PSPC1-bound RNA peaks ( Fig. 3a, right) , thereby pointing to cotranscriptional recruitment of TET2 to those loci through PSPC1-RNA interactions. We validated this observation by chromatin immunoprecipitation coupled with quantitative PCR (ChIP-qPCR), which showed that TET2 chromatin occupancy at representative loci (for example, Adss and Ywhae) that transcribe RNAs bound by PSPC1 was compromised by the loss of PSPC1 RNA-binding capacity ( Supplementary Fig. 6a ).
PSPC1 regulates endogenous retrovirus expression.
Given that recruitment of PSPC1 to chromatin is stabilized by binding of the protein to RNA, and that paraspeckle proteins have been previously implicated in transcriptional regulation 20,21 , we speculated that PSPC1 might participate in transcriptional regulation of its RNA targets. To test this hypothesis, we knocked down PSPC1 and examined global expression changes by RNA-seq. Although loss of PSPC1 function led to upregulation and downregulation of 362 and 610 coding genes, respectively (Supplementary Fig. 6b and Supplementary Table 3 ), only approximately 18% of the genes deregulated after PSPC1 depletion were bound at their RNAs by PSPC1 ( Supplementary Fig. 6c ). Gene Ontology analysis showed that genes observed to be deregulated after PSPC1 knockdown are involved in developmental processes ( Supplementary Fig. 6d ). Compared with published RNA-seq data for mouse embryos in early development 22 , we observed specific enrichment of deregulated targets in the 2C-stage embryos ( Supplementary Fig. 6e ), in which remarkable coregulation of host stage-specific genes and retrotransposable elements (REs) is prevalent 23 . REs are vestiges of ancient retroviral infections that constitute nearly 40% of the mammalian genome 24 and have been proposed to act as cis-regulatory sequences for transcriptional control of neighboring genes (reviewed in refs 25, 26 ) . Given that PSPC1 binds both coding and noncoding RNAs ( Fig. 3b ) and that only a minority of coding genes with transcribed RNAs bound by PSPC1 were affected by PSPC1 knockdown ( Supplementary Fig. 6b ,c), we hypothesized that PSPC1 might regulate gene expression by binding to REs that in turn regulate neighboring genes. In agreement with this hypothesis, further examination of CLIP-seq data showed that among PSPC1-bound RNAs other than coding ones, a vast majority arose from intergenic regions (85%) (Fig. 3b ), including LTR-containing (ERVs) and non-LTR (long and short interspersed nuclear elements) subclasses of REs ( Supplementary Fig. 7a ). The interaction between PSPC1 and RE-derived RNAs was further confirmed by RNA CLIP-qPCR experiments ( Supplementary Fig. 7b ,d,e). It is well known that ESC potency fluctuates with ERV activity 10 and that ERV expression is transcriptionally regulated by multiple epigenetic pathways 27, 28 . We discovered abundant representation of the ERVK, ERVL and MaLR ERV families among PSPC1-bound RNAs whose binding was independent of their relative abundance ( Fig. 3c and Supplementary Fig. 7c-e ), and observed global deregulation of their expression after PSPC1 depletion ( Fig. 3d and Supplementary  Fig. 7f ,g). These results suggest that the interaction of ERV RNA species with PSPC1 is required for the regulation of cellular levels of these species.
PSPC1 and TET2 participate in the repression of MERVL and adjacent genes during development.
In line with our hypothesis that ERVs bound by PSPC1 are likely to influence adjacent genes that are deregulated by PSPC1 depletion, we found that PSPC1interacting ERVs were more frequently located near the transcription start sites of PSPC1-deregulated genes than those ERV LTRs not bound by PSPC1 ( Supplementary Fig. 8a ). Notably, transcripts corresponding to MERVL elements, which are expressed in the 2C-stage embryo 23, 29 , were among the most strongly induced ERVs in the absence of PSPC1 ( Fig. 3d and Supplementary Fig. 7f ,g). In agreement with this, we observed that 2C-embryo genes that were deregulated after PSPC1 knockdown ( Supplementary Fig. 6b ) had class III ERVL elements in close proximity to their transcription start sites ( Supplementary Fig. 8b ). Using a luciferase reporter system containing the MERVL element regulating the 2C-stagespecific gene Zfp352 30 , we further confirmed PSPC1-mediated repression ( Supplementary Fig. 8c ). Moreover, we also demonstrated that artificial activation of endogenous MERVL by a CRISPR SAM (synergistic activation mediator) system 31 could recapitulate PSPC1 depletion in derepressing those PSPC1 bound and unbound 2C-stage-specific genes ( Supplementary Fig. 8d,e ). Thus, our results are consistent with the critical roles of ERVs in shaping the evolution of gene regulatory networks that underlie early embryonic development 32 . In addition, we identified RNA-binding-dependent control of ERV expression, which was exemplified by the repressive effect of PSPC1 on MERVL and evident in the MERVL repression in Pspc1-KO ESCs rescued by wild-type PSPC1, but not by PSPC1Mut ( Fig. 3e ).
To gain insight into the molecular mechanisms by which PSPC1 represses MERVL elements, we investigated the contribution of its interacting partner TET2 to the observed repression. We found that TET2 was also able to bind LTR-containing elements, such as MERVL, IAP and MusD, as well as non-LTR elements, and, more important, that such interactions were also dependent on PSPC1 ( Fig. 3f and Supplementary Fig. 9a,b ). Depletion of TET2 ( Fig. 3g and Supplementary Fig. 9c ) in ESCs caused expression changes in these REs similar to those observed after PSPC1 depletion ( Fig. 3d and Supplementary Fig. 7f,g) , and comparable to, if not more significant than, the transcriptional deregulation of these REs in ESCs lacking other well-known ERV regulators such as Trim28 and Ehmt2 28, 30, 33 ( Supplementary Fig. 10a-d) . These results suggest that the PSPC1-TET2 partnership may be critically involved in the regulation of REs whose expression is dynamically controlled during early embryonic development 23 .
MERVL expression peaks at the 2C stage of embryonic development and is greatly reduced by the blastocyst stage 23 . To validate our ESC data for PSPC1/TET2-mediated MERVL regulation in an in vivo developmental setting, we injected small interfering RNAs (siRNAs) targeting Pspc1 or Tet2, or a nontargeting control siRNA, into mouse zygotes and cultured those embryos in vitro until the blastocyst stage ( Fig. 3h and Supplementary Fig. 11a,b ). In line with previous reports on the dispensability of PSPC1 34 and TET2 35 for early development, we did not observe any significant delay in embryonic development after knockdown of PSPC1 or TET2. However, we observed derepression of MERVL elements and MERVL-associated genes during early development after depletion of either PSPC1 or TET2 ( Fig. 3h and Supplementary  Fig. 11c -f). These results show that both PSPC1 and TET2 participate in the regulation of MERVL elements and their adjacent genes during development.
Differential regulation of PSPC1-bound ERV families by TET2.
To understand how PSPC1 might cooperate with TET2 to regulate ERV expression, we examined the correlation between our PSPC1 CLIP-seq peaks and enrichment of 5hmC and 5mC at the DNA level in ESCs 36 . In contrast to the high enrichment of 5mC/5hmC on nonrepetitive coding sequences bound by PSPC1, 5mC and 5hmC were barely detectable at LTR-containing genomic loci ( Supplementary Fig. 12a ). Whereas 5hmC was absent in MERVL genomic loci, this epigenetic mark was readily detectable at the DNA of those class II ERV elements whose proper activation was dependent on PSPC1 RNA-binding ability and TET2 presence (i.e., IAP and MusD; Supplementary Figs. 7h, 9c and 12d), consistent with 5hmC-mediated DNA demethylation and transcriptional activation. These results indicate distinct mechanisms for the regulation of class II (IAP, MusD) and class III (MERVL) ERVs by PSPC1 and/or TET2, and also suggest that catalytic-activity-dependent and -independent functions of TET2 may be involved in the transcriptional activation of class II ERVs IAP and MusD and repression of class III ERV MERVL elements, respectively. TET2 mediates 5-hydroxymethylation of MERVL RNAs. To further understand these distinct regulatory mechanisms, we rescued Tet1/2/3 triple-knockout (Tet-TKO) ESCs with wild-type TET2 or a catalytic mutant form of TET2 (TET2Mut) ( Supplementary  Fig. 12c ). As expected, we found that TET2Mut did not rescue IAP and MusD expression in Tet-TKO cells ( Supplementary Fig. 12d ). To our surprise, we also found that TET2Mut could not efficiently rescue MERVL repression observed in cells rescued by wild-type TET2 (Fig. 4a ), which suggests that the catalytic activity of TET2 probably contributes to MERVL repression, possibly through a DNA-independent mechanism.
Recent findings identified 5hmC as an epigenetic mark on RNA species in mammalian 5, 6, 8, 37 and nonvertebrate organisms 7 , but the functional aspects of this RNA epigenetic modification remain poorly defined. We therefore decided to determine whether PSPC1 and TET2 could mediate 5hmC modification of MERVL transcripts, and how such RNA modification might control MERVL abundance. We immunoprecipitated DNA-free RNA by using an antibody raised against 5mC or 5hmC, and identified MERVL and MERVLchimeric transcripts, but not IAP or MusD, among 5hmC-modified RNAs in ESCs ( Supplementary Fig. 13a-d ). We also confirmed the presence of 5mC-modified MERVL transcripts (data not shown), in agreement with a recent report on global 5mC profiling of poly(A) RNA in mouse ESCs 38 . We found that the PSPC1-TET2 complex could bind both 5mC-and 5hmC-modified RNAs in vitro, although with a much weaker affinity for the latter ( Supplementary  Fig. 13e ). The observation that PSPC1-TET2 had a much higher affinity for 5mC-modified than for 5hmC-modified RNAs suggests a possibly predominant 5mC 'reader' function of TET2 that is followed by its 'writing' function in the oxidation of 5mC to 5hmC, thereby causing the subsequent release of the protein complex from RNA ( Supplementary Fig. 13f ). To confirm the functional contribution of TET2 to MERVL 5hmC modification, we carried out a rescue experiment, and observed that only wild-type TET2, and not TET2Mut or either TET1 or TET3, rescued 5hmC levels on MERVL transcripts in Tet-TKO cells ( Fig. 4b and Supplementary  Fig. 14a ). Consistent with PSPC1-dependent RNA association of TET2 ( Fig. 2d and Supplementary Figs. 5a and 9a ), only the rescue of Pspc1-KO cells with RNA-binding-competent PSPC1 (wild-type PSPC1) restored the 5hmC modification on MERVL transcripts (Fig. 4c ). These results establish the requirement of PSPC1 and TET2 for 5hmC modification of MERVL RNAs. 5hmC modification of MERVL RNAs leads to their destabilization. Given that previous studies have shown that the 5hmC precursor, 5mC, can have stabilizing effects on mRNA 39, 40 , and that MERVL abundance is increased after the loss of TET2 and PSPC1 (Fig. 3e,g and Supplementary Figs. 7f and 9c), we evaluated the effects of 5hmC deposition on the stability of MERVL transcripts. To this end, we monitored MERVL levels after transcription inhibition with α -amanitin or after pulsed incorporation of 5-ethynyl uridine in wild-type, Pspc1-KO and Tet2-KO ESCs. Our analyses showed a significant increase in the stability of MERVL transcripts in cells depleted of PSPC1 or TET2 compared with that in wild-type cells ( Fig. 4d and Supplementary Fig. 14b,c) , which correlated strongly with the absence of 5hmC in these transcripts (Fig. 4b,c ). Moreover, we obtained similar results when we treated cells with the transcriptional inhibitor triptolide (data not shown). To further investigate the hypothesis that 5hmC deposition on MERVL transcripts facilitates their destabilization, we identified PSPC1 consensus RNA-binding motifs and carried out a minigene reporter (d2EGFP) assay to assess the effect of PSPC1 binding on EGFP stability ( Supplementary  Fig. 14d,e ). We found that some of the PSPC1 binding motifs (motifs 1, 4 and 5), when fused to the d2EGFP minigene, mediated a substantial decrease in EGFP protein expression, evident in the reduced mean fluorescence intensities of wild-type versus mutant motifs after α -amanitin treatment ( Supplementary Fig. 14f ). These results indicate that 5hmC deposition on MERVL transcripts facilitates their degradation, and that the PSPC1-TET2 partnership contributes to MERVL destabilization in ESCs ( Supplementary Fig. 13f ).
The PSPC1-TET2 complex recruits HDAC1/2 for MERVL transcriptional repression. We noted that the rescue of Tet-TKO cells with TET2Mut could lead to a modest yet appreciable decrease in MERVL expression, although to a lesser extent than observed in cells rescued by wild-type TET2 (Fig. 4a ), which suggested that the catalytic activity of TET2 and 5hmC-mediated RNA degradation might not be the only mechanism for MERVL repression. In line with this, a recent study showed that TET2 can mediate transcriptional repression in chromatin in a catalytic-activity-independent fashion through histone deacetylase (HDAC) complexes in leukemia cells 41 . Indeed, HDACs were among the TET2 partners in our interactome ( Supplementary Table 1 ), and we confirmed the interaction of both HDAC1 and HDAC2 (HDAC1/2) with PSPC1 ( Supplementary Fig. 15a,b ). In addition, we detected a reduction in HDAC1/2 occupancy in MERVL loci in the absence of PSPC1 ( Supplementary Fig. 15c ). Such PSPC1-dependent HDAC1/2 binding to MERVL loci is also reliant on PSPC1 RNA-binding capacity, as demonstrated by the lack of HDAC1/2 binding in Pspc1-KO cells rescued with PSPC1Mut compared with that in cells rescued by wild-type PSPC1 ( Supplementary Fig. 15c ). These data suggest that HDAC1/2 and/or other HDAC activity could mediate the transcriptional repression of MERVL. Consistent with this, both chemical inhibition of HDAC activity by valproic acid and shRNA-mediated knockdown of Hdac1/2 led to increased expression of MERVL and MERVL-associated genes (e.g., Zfp352) ( Supplementary Fig. 15d,e ), in line with what we observed after PSPC1 and TET2 depletion. The repressive activity of HDAC1/2 on MERVL expression was dependent on the presence of RNA-binding-competent PSPC1, and was independent of TET2 catalytic activity ( Supplementary Fig. 15f ). These observations suggest that PSPC1 and TET2 may also act together with HDAC1/2 for transcriptional silencing of MERVL and its associated gene regulation, in a manner independent of TET2 catalytic activity and distinct from the well-recognized epigenetic mechanism via histone methylation 28, 30 (Supplementary Fig. 15g ).
Discussion
Here we sought to understand how TET2 is recruited to chromatin for epigenetic control in pluripotent stem cells. Our interactome study in mouse ESCs not only identified the well-known TET2 partner protein OGT 19, 42, 43 , thus validating the approach, but also uncovered novel interacting partner proteins, in particular the two RNA-binding proteins NONO and PSPC1 (Fig. 1) . Both NONO and PSPC1 are components of paraspeckles with functions in RNA processing, nuclear retention of mRNA, and stress response 44, 45 . However, ESCs do not form paraspeckles 21, 44 , and NONO was recently found to be a bivalent chromatin domain factor that regulates mouse ESC pluripotency through Erk signaling, the lack of which stabilizes ESCs in a naive pluripotent state 21 . In contrast, the potential roles of PSPC1 in stem cells are not known. Our study establishes PSPC1 as an important recruiter of the epigenetic regulators TET2 and HDAC1/2 to actively transcribed MERVL loci for a dual transcriptional and post-transcriptional repression of MERVL in pluripotent stem cells. Specifically, PSPC1 recruits TET2 for the deposition of 5hmC onto class III ERVL RNAs, thereby leading to their destabilization, while facilitating concomitant recruitment of HDAC activity to repress their transcription in mouse ESCs (Fig. 4e) . Although high-resolution mapping of RNA-binding regions in the nuclear proteome of ESCs identified the potential RNA-binding capacity of TET2 46 , our study indicates that the majority of TET2 RNA binding is dependent on PSPC1 and its RNA-binding domains ( Figs. 2d and 3f , and Supplementary Fig. 5a ).
ERVs are well recognized for their contribution to host genome evolution and gene regulatory networks, and their aberrant regulatory activities also are linked to pathological and oncological conditions 9, 25, 26, 47, 48 . Pluripotent embryonic cells serve as the 'battleground' for an evolutionary arms race between transposable elements and the host genome during development 9 , and reactivation of MERVL and its co-opted 2C genes has been correlated with totipotent features in 2C embryos 10, 32 and 2C-like cells within pluripotent ESC cultures 10, 49 . While transcriptional and epigenetic control of ERVs via DNA (de)methylation and histone modifications are well established, our study suggests that ERV transcripts can also be post-transcriptionally regulated via TET-mediated RNA hydroxymethylation. This is in line with the recognition that multiple silencing mechanisms involving TET enzymes act in concert to control retrotransposon activity in pluripotent cells 50 . In particular, our study provides potential insights into the unique dynamic cyclic fluctuation between totipotent 2C-like cells and pluripotent ESCs in culture that is regulated by PSPC1 and TET2 at the posttranscriptional level via an RNA-hydroxymethylation-mediated mechanism (Fig. 4e ). However, our findings on RNA-dependent chromatin targeting of TET2 for ERV control were not universal, but varied depending on ERV classes. This is evident in the fact that the PSPC1-TET2 partnership had a positive effect on the expression of class IIERVK family members IAP and MusD (Fig. 3c,d) via PSPC1-TET2-mediated transcriptional activation ( Supplementary  Figs. 7h and 12b,d) . Future studies will be needed to dissect such transcriptional activation mechanisms for class II ERVs, as well as to investigate how other TET members (e.g., TET1) may participate in ERV control. In this regard, it is interesting to note that TET1 does not bind MERVL genomic loci for transcriptional regulation of MERVL 51 or contribute to 5hmC MERVL RNA hydroxymethylation ( Supplementary Fig. 14a ).
In sum, our study provides a paradigm for post-transcriptional silencing of class III ERV (i.e., MERVL) RNAs via 5hmC modification, facilitated by an RNA-binding protein (i.e., PSPC1), which mediates TET2 recruitment. As ERV reactivation has been widely related to aging, cancer and autoimmune diseases 47, 48 , our findings should also open new avenues for exploring post-transcriptional ERV control by RNA hydroxymethylation in health and disease.
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Methods
Murine embryonic stem cell culture. ESCs were grown under standard culture conditions. Briefly, cells were cultured on 0.1% gelatinized (Gibco, 214340) tissue culture plates in medium containing high-glucose DMEM (Gibco, 11965-092), 15% FBS (Corning, 35-010-CV), 100 µ M nonessential amino acids (Gibco, 11140-050), 2 mM l-glutamine (Gibco, 25030-081), 1% nucleoside mix (Sigma; U3003, A4036, C4654, T1895, G6264), 100 U/ml penicillin, 100 µ g/ml streptomycin (Gibco, 15140-122), 8 nl/ml 2-mercaptoethanol (Sigma, M6250) and homemade recombinant leukemia inhibitory factor tested for efficient self-renewal maintenance.
Affinity purification of TET2 protein complexes in ESCs. The Tet2:FLAG knockin ESC line was generated with a targeting vector containing a Neo cassette flanked by two FRT sites, followed by a 0.5-kb genomic fragment upstream of the Tet2 start codon and an ATG/3×FLAG/V5 sequence. 2.2-kb 5′ and 4.8-kb 3′ arm genomic fragments were subcloned into the vector for gene targeting. The targeting vector was linearized and electroporated into 129/sv mouse ESCs, and positive clones were screened by Southern blotting.
We used two independent affinity-purification approaches to isolate TET2 protein complexes for mass spectrometry (MS) identification. In the first approach, nuclear extracts from both wild-type (WT) and Tet2 knock-in ESC lines were prepared as previously described 52 . Briefly, five large square dishes (245 × 245 mm) of each cell line were washed with PBS and scraped, and the cytoplasmic fraction was removed by incubation with buffer A (10 mM HEPES, pH 7.6, 1.5 mM MgCl 2 , 10 mM KCl) supplemented with proteinase inhibitors. Afterward, nuclear pellets were incubated with buffer C (20 mM HEPES, pH 7.6, 25% glycerol (v/v), 0.42 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA) supplemented with proteinase inhibitors. Finally, the salt concentration was decreased to 100 mM by dialysis with buffer D (20 mM HEPES, pH 7.6, 0.2 mM EDTA, 1.5 mM MgCl 2 , 100 mM KCl, 20% glycerol (v/v)) at 4 °C for 3 h, and unwanted precipitated proteins were removed by centrifugation. Freshly made nuclear extracts were pre-cleared with 0.5 ml of Protein G agarose beads (Roche, 11243233001) for 1 h at 4 °C in the presence of 750 units of Benzonase (Fisher Scientific, 502308706) to remove DNA and RNA followed by incubation with 0.5 ml of anti-Flag M2 agarose beads (Sigma, F2426) for 3 h at 4 °C. After five washes in buffer D supplemented with 0.02% NP-40 (v/v), the 3× Flag-tagged TET2 protein complexes were eluted four times for 1 h each time at 4 °C, with 0.3 mg/ml 3× Flag peptide in buffer D supplemented with 0.02% NP-40 (v/v). After concentration, protein complexes were boiled for 5 min with Laemmli sample buffer and separated in a 10% SDS-PAGE gel.
For the second approach, we used SILAC IP-MS for which WT and Tet2 knock-in ESC lines were cultured in medium labeled by l-arginine-HCL and l-lysine-2HCL (Thermo Scientific, 88427) (light) or by l-arginine-HCL (U-13C6, 99%; U-15N4, 99%) (Cambridge Isotope Laboratories, CNLM-539-H-0.25) and l-lysine-2HCL (U-13C6, 99%; U-15N2, 99%) (Cambridge Isotope Laboratories, CNLM-291-H-0.25) (heavy) amino acids. Nuclear extracts were pre-cleared and immunoprecipitated with anti-Flag M2 agarose beads as described above. Immuno-bound complexes from each cell line were combined in a 1:1 ratio before the last wash after immunoprecipitation and elution with 3× Flag peptide (Sigma, F4799) as described above. Protein complexes were concentrated and boiled with Laemmli sample buffer and separated by SDS-PAGE. In both instances, SDS-PAGE gels were stained with GelCode Blue Safe Protein Stain buffer (Thermo, PI-24594) and subjected to whole-lane LC-MS/MS analysis.
Mass spectrometry data analysis. MS data were processed by Thermo Proteome Discoverer software with SEQUEST engine against the International Protein Index mouse protein sequence database (v.3.68). Protein lists were filtered according to the minimal number of identified peptides (> 2). Common contamination proteins (e.g., trypsin, keratins, actin, tubulins) were removed. Duplicated records were removed on the basis of unique protein symbols. Then the protein enrichment ratio was calculated on the basis of the heavy/light ratio (SILAC) or spectrum counts (label-free) of TET2 pulldown versus control pulldown.
Coimmunoprecipitation and western blotting. Nuclear extracts from
ESCs (mouse ESC line CCE) prepared as described above were incubated with the corresponding antibodies overnight at 4 °C. A fraction of lysate was kept as input. On the second day, equilibrated Dynabeads G (Life Technologies, 10004D) or anti-MYC agarose affinity gel (Sigma, A7470) was added to each reaction and rotated for 4 h at 4 °C. Bound beads were then washed with immunoprecipitation buffer. Immunoprecipitated proteins were visualized by western blotting with the following primary antibodies: anti-PSPC1 (Santa Cruz, sc-84577), anti-TET2 (Abcam, ab124297), anti-Flag (Sigma, F1804), anti-β -actin (Sigma, A5441) anti-GAPDH (Protein Technologies, 10494-1-AP), anti-OCT4 (Santa Cruz, sc-5279) and anti-histone H3 (Abcam, ab1791). True-blot secondary antibodies were used to reduce the detection of IgG used for immunoprecipitation. Western blot bands were quantified with ImageJ software.
Lentiviral infection for shRNA knockdown. Small hairpin RNAs (shRNAs) for
Pspc1 knockdown were designed, synthesized and subcloned into pLKO.1 vectors (Addgene) expressing a puromycin-resistance gene and an mCherry reporter.
Lentivirus production and infection were performed as described 53 . All shRNA sequences are provided in Supplementary Table 4 .
RNA extraction and analysis by quantitative PCR.
Total RNA from ESCs, induced pluripotent stem cells and mouse embryonic fibroblasts was extracted with the RNeasy kit (Qiagen, 74136) and converted to cDNA with qSCRIPT (Quanta, 95048). Gene expression was analyzed with Lightcycler 480 SYBR Green master mix (Roche, 4729749001) on the LightCycler480 real-time PCR system (Roche).
We dissected one adult male and one adult female mouse to isolate organs of interest. Thirty milligrams of each tissue were disaggregated with QIAshredder columns (Qiagen, 79656). Total RNA was extracted with an RNeasy kit and subjected to reverse transcription and qPCR quantitation according to the manufacturer's instructions.
RNA from 1.5-, 2.5-and 4.5-dpc (days post-coitum) embryos injected with siRNAs was extracted with TRIzol (Thermo Fisher, 15596026) according to the manufacturer's instructions. Total purified RNA was subjected to reverse transcription as described above, and expression was quantified by qPCR.
Primers used in this study are shown in Supplementary Table 4 . In all cases, average threshold cycles were determined from triplicate reactions, and the levels of gene expression were normalized to those of a housekeeping gene as indicated (Hprt, Rnu6 or Actb). Error bars in figures indicate s.e.m. or ranges of fold change relative to the reference sample, as indicated in the legends.
Preparation of whole-cell extracts and chromatin-bound protein fractions.
We obtained whole-cell protein extracts by lysing cell pellets in RIPA buffer (60 mM Tris-HCl, pH 6.8, 2% SDS (v/v), 10% glycerol (v/v) and 10 mM DTT) supplemented with PMSF and proteinase inhibitors. Chromatin-bound protein fractions were prepared with a chromatin extraction kit (Thermo Scientific, PI-78840) according to the manufacturer's instructions.
Immunofluorescence. Cells were grown on 24-well plates coated with 0.1% gelatin (w/v). After fixation with 4% paraformaldehyde (w/v) for 15 min at room temperature (RT), cells were permeabilized with 0.25% Triton X-100 (v/v) in PBS for 5 min at RT and blocked with 10% BSA (AMRESCO) for 30 min at 37 °C. For immunostaining, cells were incubated overnight at 4 °C with primary antibodies anti-SOX2 (Santa Cruz, sc-17320), anti-PSPC1 and anti-OCT4 in PBS with 3% BSA (w/v). The next day cells were incubated with fluorophore-labeled secondary antibodies for 1 h at RT. Cells were imaged with a Leica DMI 6000 inverted microscope at 20× magnification. 
CRISPR-Cas9 generation of Pspc1-knockout ESC line. Pspc1-KO mouse ESCs
were generated with the CRISPR editing tool as described 54 . Briefly, an sgRNA (Supplementary Table 4 ) was designed to target the transcription start site of Pspc1, using the guidelines described in MIT's online tool ("URLs"), and cloned into the pX330 vector (Addgene #42230) modified to have a GFP reporter gene. ESCs were transfected with the plasmid containing the sgRNA and GFP reporter, and GFP + ESCs were sorted 48 h after transfection and seeded at clonal density. One week later, clones were picked and analyzed for PSPC1 expression by western blotting, and the Pspc1 CRISPR-Cas9-targeted genomic region was PCR-amplified and sequenced in Pspc1-KO clones.
CRISPR activation of MERVL. CRISPR activation of MERVL expression was achieved by the Synergistic Activation Mediator (SAM) 31 using a three-vector system: dCAS-VP64-Blast (Addgene #61425), MS2-P65-HSF1-Hygro (Addgene #61426) and MS2-sgRNA-Zeo (Addgene #61427), where the non-targeting or MERVL-targeting (+ 317F4 from gag ATG) sgRNAs were cloned using BsmBI restriction sites. Lentiviruses containing each of the plasmids were generated, and ESCs were infected with a 1:1:1 mix of the viruses in the presence of 8 µ g/ml Polybrene. Infected cells were selected for 48 h with 10 µ g/ml blasticidin, 250 µ g/ml hygromycin and 250 µ g/ml Zeocin. Selected cells were collected for total RNA isolation and qPCR analysis.
Chromatin immunoprecipitation coupled with qPCR. ChIP assays were performed as previously described 55 . Briefly, we cross-linked cells with 1% (w/v) formaldehyde for 10 min at RT, and then added 125 mM glycine to stop the reaction. Chromatin extracts were sonicated into 200-500 bp and immunoprecipitated with anti-TET2, anti-Flag, anti-PSPC1, anti-HDAC1 (Bethyl, A300-713A), anti-HDAC2 (Bethyl, A300-705A), anti-H3K9me2 (Abcam, ab1220) or IgG (Millipore, PP64). The immunoprecipitated DNA was purified with ChIP DNA Clean & Concentrator columns (Zymo Research) and analyzed by qPCR with Roche SYBR Green reagents and a LightCycler480 machine. Primer sequences are listed in Supplementary Table 4 . Percentages of input recovery were calculated.
In vitro RNA-binding assay. Whole-cell extracts from WT, Pspc1-KO or rescued cells were prepared as previously described. Two milligrams of protein extracts were incubated with 2 µ g of anti-TET2 or anti-PSPC1 in the presence of RNase A and DNase I nucleases, to avoid contamination of endogenous RNA or DNA. TET2 or PSPC1 protein complexes were recovered by incubation with 20 µ l of Protein G magnetic Dynabeads (Invitrogen) for 4 h at 4 °C. After washing, purified protein complexes were incubated with total RNA for 30 min at RT. Total RNA was obtained from mouse ESCs by TRIzol (Invitrogen) extraction and purification according to the manufacturer's instructions, followed by Proteinase K and DNase I treatment. Beads containing protein-RNA complexes were then washed and eluted in TRIzol, and immunoprecipitated RNA was purified. RNA was treated with or without RNase A (Thermo Fisher, EN0531) and quantified with the Qubit High Sensitive assay kit (Life Technologies, Q32852). Immunoprecipitated RNA was visualized in an ethidium bromide agarose gel and retrotranscribed with qSCRIPT (Quanta, 95048) for analysis by qPCR.
RNA immunoprecipitation of cross-linked cells. Cross-linked nuclear extracts
were prepared in the same way as ChIP extracts, described above. After sonication, nuclear extracts were incubated with 1.5 µ g of the corresponding antibody (IgG, anti-PSPC1 or anti-TET2) pre-bound to 25 µ l of Dynabeads Protein G (Thermo Fisher, 10004D) in the presence of proteinase and RNase inhibitors (Thermo Scientific, AM2694 and 10777019) overnight with rotation at 4 °C. After washing, immuno-complexes were eluted with 100 µ l of elution buffer (10 mM Tris-HCl, pH 8.0, with 1 mM EDTA) and RNA was extracted with TRIzol. Immunoprecipitated RNA was treated with DNase I and with or without RNase A, after which it was subjected to phenol:chloroform extraction. The resulting RNA was retrotranscribed with qScript, and cDNA was visualized in a polyacrylamide gel by silver staining (Thermo Scientific, 24600) according to the manufacturer's instructions.
UV-cross-linking and RNA immunoprecipitation coupled with qPCR.
Cells were trypsinized and UV-cross-linked according to previously published protocols 56 . Briefly, cells were irradiated at 400 mJ/cm 2 in a CL-1000 UVP UVcross-linker and then subjected to cell lysis by incubation with nuclear suspension buffer (248 mM sucrose, 8 mM Tris-HCl, pH 7.5, 4 mM MgCl 2 , 0.1 mM DTT, 0.8% Triton X-100 (v/v)) in the presence of protease and RNase inhibitors. Nuclear pellets were obtained by centrifugation, and nuclear content was released by incubation in RIP buffer (150 mM KCl, 25 mM Tris-HCl, pH 7.5, 5 mM EDTA, 0.5 mM DTT, 0.5% NP-40 (v/v)) in the presence of protease and RNase inhibitors, and subjected to brief sonication to help break the nuclear envelope. Immunoprecipitation of PSPC1 or TET2 and purification of their target RNAs were performed as described above.
α-Amanitin and valproic acid treatments. Cells in culture were treated with 10 µ g/ml α -amanitin (Santa Cruz, sc-202440), an inhibitor of RNA Pol II and Pol III, or with Milli-Q water control (vehicle) for 0, 1, 2 or 4 h. For HDAC inhibition, cells were cultured in the presence of 0.5 µ M class I HDAC inhibitor valproic acid (Stemgent, 04-0007) or DMSO control (vehicle) for 24 h. For both experiments, cells were collected and processed for western blotting or qPCR analysis.
RNA stability assay by nascent RNA capture. To monitor RNA degradation, we treated ESCs with 0.2 mM 5-ethynyl uridine (EU) in growth medium for 16 h. Total RNA was extracted at 0 h and 8 h after the removal of EU from culture medium. EU-labeled RNAs were biotinylated and captured with the Click-iT nascent RNA capture kit (Invitrogen, C10365) according to the manufacturer's instructions. RNA was reverse-transcribed with SUPERSCRIPT IV VILO (Invitrogen, 11756050) and quantified by qPCR.
Cross-linking immunoprecipitation and massive parallel sequencing. UV cross-linking and immunoprecipitation were performed as described 57 , with some modifications. Briefly, J1 mouse ESCs expressing a 3× Flag-biotin-tagged PSPC1 construct were cross-linked in PBS with UV type C (254 nm) at 600 mJ/cm 2 on ice. Cells were harvested, pelleted, and lysed in PXL lysis buffer (1× PBS, 0.1% SDS (w/v), 0.5% NP-40 (v/v) and 0.5% sodium deoxycholate (w/v)) supplemented with proteinase and RNase inhibitors and RQ1 DNase (Promega, M6101). After 30 min of incubation on ice, cells were centrifuged, and the supernatant was carefully collected. For immunoprecipitation, the supernatant was incubated with beads prebound with 4 µ g of anti-Flag conjugated with 30 µ l of Protein G Dynabeads overnight at 4 °C. After immunoprecipitation, the sample was washed with PXL lysis buffer twice and then with high-salt buffer twice (5× PBS, 0.1% SDS (w/v), 0.5% NP-40 (v/v), 0.5% sodium deoxycholate (w/v)). Then the protein-RNA complex was subjected to MNase digestion (New England BioLabs (NEB), M0247). To dephosphorylate RNA, we incubated each immunoprecipitated sample in 80 µ l of 1× reaction mixture including 3 µ l of CIP (NEB, M0290S) for 10 min at 37 °C. After the CIP treatment, the immunoprecipitates were washed twice with PNK + EGTA buffer (50 mM Tris-HCl, pH 7.4, 20 mM EGTA, and 0.5% NP-40 (v/v)) and twice with PNK buffer (50 mM Tris-HCl, pH 7.4, 10 mM MgCl 2 , and 0.5% NP-40 (v/v)). To ligate the 3′ linker, we incubated each of the washed immunoprecipitates in 40 µ l of 1× ligation reaction mixture with 80 pmol of 3′ linker (Takara; Supplementary Table 4 ) and 3 µ l of truncated T4 RNA ligase 2 (NEB, M0242) overnight at 16 °C. After the reaction, immunoprecipitates were washed twice with PXL buffer and twice with PNK buffer. Then we phosphorylated the RNAs by incubating the immunoprecipitates in 1× reaction mixture containing 2 µ l of T4 PNK (NEB, M0201) and 1 µ l of hot ATP (PerkinElmer) for 5 min at 37 °C to label the RNA-protein complexes. After the labeling, 5 µ l of 2 mM ATP was added and the mixture was incubated for another 5 min at 37 °C. After PNK treatment, immunoprecipitates were washed four times with PNK buffer and mixed with 2× LDS loading dye (Invitrogen, NP0007). The samples were incubated at 70 °C for 10 min to elute RNA-protein complexes from the beads. Immunoprecipitated RNA was loaded onto a NuPage SDS gel and transferred onto a nitrocellulose membrane.
For RNA isolation, nitrocellulose membranes were fragmented with a clean scalpel blade and treated with 4 mg/ml proteinase K (Takara, 9034) in 200 µ l of PK buffer (100 mM Tris-HCl, pH 7.4, 50 mM NaCl, 10 mM EDTA) for 20 min at 37 °C, and incubated in 200 µ l of PK + urea buffer (100 mM Tris-HCl, pH 7.4, 50 mM NaCl, 10 mM EDTA, and 7 M urea) for another 20 min at 37 °C. RNA was extracted with TRIzol and ligated with 5′ RNA linkers ( Supplementary Table 4 ) for 16 h at 16 °C. We carried out reverse transcription with RT primer followed by PCR with forward SR and reverse index primers (all are listed in Supplementary Table 4 ) for 25 cycles to generate and amplify the cDNA library, respectively. High-throughput sequencing of the resulting cDNA was performed on a HiSeq-2000 sequencer.
CLIP-seq analysis. CLIP-seq reads were aligned to the mouse genome (mm9) using TopHat (v2.0.10) and Bowtie2 (v2.1.0) with the default parameter settings. CLIP-seq peaks were determined with the Piranha tools ("URLs") with the parameters -s -b 200 and annotated with the "annotatePeaks" module in HOMER (v4.6) against the mm9 mouse genome.
Motif finding in CLIP-seq. CLIP-seq peaks were used as input for de novo motif discovery in HOMER with the parameters "-rna -len 6" and the mm9 reference genome.
RNA stability reporter assay. To generate the mRNA stability minigene construct, we cloned the top five consensus motifs of PSPC1 CLIP-seq upstream of the EGFP coding sequence in the pd2EGFP-N1 vector (BD Biosciences). This vector expresses a destabilized version of EGFP protein with a half-life of 2 h, which is useful for studies that require rapid reporter turnover. To design the sequence surrounding the motifs, we specifically chose sequences enriched in the MERVL RNA sequence with CG regions (Supplementary Table 4 ). We designed the corresponding mutated motifs by replacing cytosines with adenines in each motif. All the motifs were cloned with XhoI and BamHI sites into the reporter vector. Each vector was transfected with JetPrime polyplus reagent into ESCs in 48 wells. The next day, we added 10 μ g/ml of α -amanitin (or vehicle (Milli-Q)) to the medium to inhibit transcription. Cells were analyzed by flow cytometry with an Accuri C6 instrument (BD Biosciences), and data were analyzed with FlowJo software (Treestar). The mean fluorescence intensity of EGFP, an indicator of RNA stability, was gated on the GFP + singlet population.
ChIP-seq, methylated DNA immunoprecipitation sequencing and hydroxymethylated DNA immunoprecipitation sequencing analysis. External data for ChIP-seq, methylated DNA immunoprecipitation sequencing (MeDIPseq) and hydroxymethylated DNA immunoprecipitation sequencing (hMeDIP-seq) analysis were downloaded from GEO (5mC, GSM611203; 5hmC, GSM611199; TET2, GSM1023124). Reads were aligned to the mouse genome (NCBI build 37, mm9) using Bowtie (v1.0.0), with parameters -M 1 --best --chunkmbs 200. The duplicated reads of the aligned data were removed, then filtered reads were sorted with SAMtools (v0. 1.19) . For LTR sequence annotation, analysis was performed as described 58 . Briefly, RepeatMasker track (RMSK) from UCSC Genome Browser was used, and ChIP-seq intensity at each LTR region was measured by HTseq software (v0.6.1) with parameters -a 10 -m intersection-nonempty. The ChIP-seq intensity of TET2 and 5hmC at each LTR region was normalized by total mapped reads as reads per million mapped reads (RPM).
hMeDIP-qPCR.
Genomic DNA from wild-type ESCs was isolated according to the manufacturer's instructions (Qiagen, 158388). Four micrograms of gDNA were denatured by boiling for 10 min in water and immunoprecipitated with 2.5 µ l of anti-5hmC in immunoprecipitation buffer (100 mM sodium phosphate, pH 7.0, 1.4 M NaCl and 0.5% Triton X-100 (v/v)). After 6 h of incubation at 4 °C, the immunobound DNA was recovered by the addition of 20 µ l of pre-equilibrated Dynabeads G and rotated at 4 °C overnight. The next day, beads were recovered and washed with IP buffer, antibody was removed by digestion with Proteinase K, and DNA was extracted with phenol:chlorophorm:isoamylalcohol and ethanol precipitation. Immunoprecipitated DNA was analyzed by qPCR.
RNA-seq of PSPC1-depleted ESCs.
Mouse ESCs were infected with pLKO.Puro-IRES-mCherry constructs carrying shRNAs targeting Pspc1 or control shRNAs. Biological duplicates were prepared for RNA-seq analysis, according to our previously described protocol 59 . Briefly, total RNA from each sample was extracted with an RNeasy kit, and paired-end sequencing was carried out with the Illumina HiSeq-2500 according to a RiboZero selection protocol per the manufacturer's instructions. Reads were aligned to the mouse genome (NCBI build 37, mm9) using TopHat (v2.0.10) and Bowtie2 (v2.1.0) with the default parameter settings. Transcript assembly and differential expression analysis were done with Cufflinks (v2.1.1). Assembly of novel transcripts was allowed (-g); other parameters followed the default settings. The summed FPKM (fragments per kilobase per million mapped reads) of transcripts sharing each gene_id was calculated, and the significance of differential expression tests was estimated via a genome-wide false discovery rate after Benjamini-Hochberg correction for multiple testing.
For the LTR regions, a reference genome with all LTRs was created based on the RMSK database. RNA-seq intensity at each LTR region was counted by HTseq software (v0.6.1) with parameters -a 10 -m intersection-nonempty, and normalized to total mapped reads (RPM). LTR expression in shEV (empty vector) and shPspc1 samples was compared, and P values were calculated by Student's t-test.
The PSPC1 CLIP-seq dataset was used to calculate the distance between PSPC1-bound sites and PSPC1-regulated genes. Briefly, CLIP-seq intensity at each LTR region was determined by HTseq and normalized as an RPM value. PSPC1-bound (intensity > 0.5 RPM) and PSPC1-unbound (intensity = 0) sites were collected. A subset of PSPC1-unbound sites was randomly selected from the PSPC1-unbound pool, with the same number of PSPC1-bound sites (n = 14,220). Then the distribution of distances between PSPC1-upregulated genes by RNA-seq and nearest PSPC1-bound or -unbound sites was calculated and plotted. The significance of the number of nearest PSPC1-bound versus -unbound sites (< 50 kb) was calculated by binomial test.
RNA-seq analysis of previously published datasets. External RNA-seq data for
Trim28-conditional knockout (cKO) (GSE41903) and Ehmt2-cKO (GSE33923) cells were analyzed for ERV expression as described above.
Luciferase reporter assay. Twenty thousand ESCs were transfected with 0.32 µ g of luciferase reporter plasmids containing genomic promoter fragments from the Zfp352 gene including the PSPC1-regulated LTR element 30 and 16 ng of Renilla control plasmid. The same promoter without the LTR was used as a negative control. Twenty-four hours after transfection, cells were lysed and luciferase and Renilla activity were assayed with the DualGlo luciferase assay kit (Promega, E2920) according to the manufacturer's instructions in a PerkinElmer EnSpire Alpha Luminometer. The luciferase/Renilla ratio was calculated for all the samples. Measurements were carried out in triplicate biological samples.
Mouse embryo collection and microinjection. C57BL/6JxDBA/2J (B6D2) female mice were superovulated by intraperitoneal injection of 5 IU pregnant mare's serum gonadotropin (National Hormone and Peptide Program) followed by intraperitoneal injection of 5 IU human chorionic gonadotropin (National Hormone and Peptide Program) 48 h later. The females were mated with males overnight, and one-cell embryos were collected from pregnant females in HEPESbuffered FHM media (Millipore, MR-024-D). Cumulus cells were removed by brief treatment with hyaluronidase (Millipore, MR-056-F) in FHM media. Isolated fertilized eggs (as judged by the presence of two pronuclei) were microinjected in the cytoplasm with 5-10 picoliters of 20 µ M nontargeting siRNA (GE-Dharmacon #D-001910-01-05), Pspc1 siRNA (GE-Dharmacon #E-049216-00-0005) or Tet2 siRNA (GE-Dharmacon #E-058965-00-0005) and cultured in bicarbonate-buffered KSOM media (Millipore, MR-121-D) at 37 °C with 5% CO 2 . We used a Nikon Diaphot inverted microscope equipped with a Narashige micromanipulator system for the microinjections. After injection, embryos were inspected every day for assessment of developmental progress. Total RNA was extracted for qPCR analysis and processed as described before. For each knockdown we processed around 100 injected embryos, with a 50% rate of survival. All mouse procedures were done in accordance with Mount Sinai IACUC policy. Zygote injections were done in the Mouse Genetic Shared Research Facility at Mount Sinai.
Methylated and hydroxymethylated RNA immunoprecipitation. Total RNA was sonicated to an average size of 500 bp and then subjected to immunoprecipitation with either anti-5mC (Sigma, 60612) or anti-5hmC (Active Motif, 39769) or with an IgG control antibody (Millipore, PP64) based on a previously described protocol 60 . Briefly, 6-10 µ g of sonicated RNA was incubated with 2 µ g of antibody at 4 °C overnight. The next day, 5hmC-modified RNAs were purified by incubation with 20 µ l of Dynabead Protein G beads. After being washed to reduce nonspecific background, bound RNA was eluted with TRIzol (Invitrogen) and extracted according to the manufacturer's instructions. Finally, immunoprecipitated RNAs were subjected to reverse transcription and qPCR quantitation.
RNA electrophoretic mobility shift assay. The RNA probe was synthesized by standard solid-phase synthesis using Oligo-800 DNA synthesizer with the sequence 5′ -biotin-CCUCUGCCUXCCGAAUCCAA-3′ (where X is 5mC or 5hmC). Both 5mC and 5hmC phosphoramidite building blocks were purchased from ChemGenes. The RNA oligonucleotides were deprotected by AMA (1:1 mixture of ammonium hydroxide and methyl amine solution) and Et3N• 3HF treatment, followed by ion-exchange HPLC purification on a Dionex PA-200 column. HEK293T cells were transfected with plasmids encoding 3×FL TET2 and Myc PSPC1, and total protein extracts were incubated with anti-Flag to immunopurify PSPC1-TET2 complexes. The complex was competitively eluted by 3× Flag peptide. Increasing amounts of PSPC1-TET2 protein complex (0, 0.5, 1 and 2 µ g of total protein) were incubated with 250 ng of the corresponding RNA probe in binding buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.4 mM EDTA, 0.1% NP-40 (v/v), 40 U/ml RNasin, 1 mM DTT, 50% glycerol (v/v), 5 ng/μ l BSA) for 30 min at RT. Then, 1 μ l of glutaraldehyde (0.2% final concentration) was added into the mixture, which was incubated at RT for 15 min. The total protein-RNA mixture was loaded onto a 6% TBE acrylamide gel and run for 30 min at 80 V on ice. The gel was transferred onto hybond-N + membrane (GE Healthcare, 95038-362) in 1× TBE buffer and nucleic acids were detected by the chemiluminescent nucleic acid detection module (Thermo Fisher, 89880) according to the manufacturer's instructions. Quantification of each band was carried out with ImageJ software, and the percentage of bound RNA probe was calculated as (Intensity of bound probe)/((Intensity of bound probe) + (Intensity of free probe)) × 100.
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Data availability. RNA-seq (GSE103267) and CLIP-seq (GSE103268) datasets generated in this study have been deposited in the Gene Expression Omnibus (GEO). Anti-FLAG antibody, detailed in Methods.
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Describe the peak calling parameters.
Piranha -s -b 200 9. Describe the methods used to ensure data quality. There are 15,291 clip-seq clusters were identified by Piranha, with the setting of background threshold 0.99, means 99% of the lowest scores reads are considered the background.
10. Describe the software used to collect and analyze the ChIP-seq data.
CLIP-seq reads were trimmed by the 3' adaptor sequence: AGATCGGAAGAGCACACGTCT and cleaned by Trim Galore. CLIP-seq reads were aligned to the mouse genome (mm9) using TopHat (v2.0.10) and Bowtie2 (v2.1.0) with the default parameter settings.
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Methodological details 5 . Describe the sample preparation.
ESCs were trypsinized and suspended in DPBS buffer. For Fig. S3b , cells were permeabilized and stained with DAPI.
6. Identify the instrument used for data collection. Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
June 2017
Initial submission Revised version Final submission
Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
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